Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Leiden University Medical Center
Study ID
NCT05952583
Status
Recruiting

Conditions

  • Fetal Growth Retardation
  • Twin Diseases
  • Twin Monochorionic Diamniotic Placenta
  • Twin; Pregnancy, Affecting Fetus or Newborn

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Ultrasound — DIAGNOSTIC_TEST
    Additional ultrasound measurements during pregnancy

Study Details

Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy. Furthermore, little is known about the brain development of sFGR children (both during pregnancy and after birth). Moreover, the psychological impact of an sFGR pregnancy of the future parent)s) has not been studied before. The impact of these factors should be taken into account during patient counseling, which is currently not the case. By our knowledge, this is the first international, multicenter, prospective cohort study on that will address the abovementioned questions and knowledge gaps in MCDA pregnancies complicated by selective fetal growth restriction.

Key Dates

Start date
Feb 17, 2023
Status verified
Apr 2024
Primary completion
Mar 1, 2025
Completion
Mar 1, 2028

Study Design

Enrollment
274 participants (estimated)

Arms

  • Arm: sFGR cohort
    Monochorionic diamniotic twin pregnancies complicated by sFGR (diagnosed before 28 weeks of gestational age)

Primary Outcome Measure

Composite outcome [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Boston Children's HospitalBostonMassachusetts02115
Ali Javinani, MD, PhD
Alireza Shamshirsaz, Professor, MD, PhD

Find similar trials in Boston, MA